New hope for lymphoma patients: drug may boost CAR T-Cell success
NCT ID NCT05464719
First seen Nov 19, 2025 · Last updated Jun 21, 2026 · Updated 33 times
Summary
This phase II trial tests whether the drug loncastuximab tesirine (Lonca) can help control large B-cell lymphoma in patients who had only a partial response after CAR T-cell therapy. About 30 adults with relapsed or refractory lymphoma will receive Lonca intravenously. The main goal is to see if it can turn a partial response into a complete response, while also monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
loncastuximab tesirine (Lonca)
What this could lead to
If successful, this could offer a new option to achieve complete remission in patients whose lymphoma only partially responded to CAR T-cell therapy.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug may cause side effects and may not improve outcomes for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.